PHAR Valuation

Pharming Group NV

Add to Watchlist

Advanced Chart

10.191

+0.091(0.901%)1D

Overview
Forecast
Valuation
Earnings

PHAR Relative Valuation

PHAR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PHAR is overvalued; if below, it's undervalued.

Historical Valuation

Pharming Group NV (PHAR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.04 is considered Undervalued compared with the five-year average of -90.98. The fair price of Pharming Group NV (PHAR) is between 791.63 to 796.93 according to relative valuation methord. Compared to the current price of 10.10 USD , Pharming Group NV is Undervalued By 98.72%.

Relative Value

Fair Zone

791.63-796.93

Current Price：10.10

98.72%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

31.58

P/B

Median3y

8.17

Median5y

6.42

0.73

FCF Yield

Median3y

-0.04

Median5y

2.95

Competitors Valuation Multiple

The average P/S ratio for PHAR's competitors is 686.10, providing a benchmark for relative valuation. Pharming Group NV Corp (PHAR) exhibits a P/S ratio of 2.08, which is -99.70% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap